HR-Positive, HER2-Negative Breast Cancer Specialty Channel

HR+/HER2– Breast Cancer

Specialty Channel

Conference Coverage

Addition of Ribociclib Decreases Risk of Invasive and Distant Disease Recurrence Among Patients With HR-Positive, HER2-Negative Breast Cancer

10/04/2024

Stephanie Holland ;

Landmark 4-year analysis results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment significantly decreases the risk of invasive and distant disease recurrence among...

Landmark 4-year analysis results...

10/04/2024

Oncology

News

Conference Coverage

Addition of Ribociclib Decreases Risk of Invasive and Distant Disease Recurrence Among Patients With HR-Positive, HER2-Negative Breast Cancer

10/04/2024

Stephanie Holland ;

Landmark 4-year analysis results...

10/04/2024

Oncology

Recent News

Conference Coverage

Addition of Ribociclib Decreases Risk of Invasive and Distant Disease Recurrence Among Patients With HR-Positive, HER2-Negative Breast Cancer

10/04/2024

Stephanie Holland ;

Landmark 4-year analysis results...

10/04/2024

Oncology

FDA Alerts

FDA Approves Multitarget Stool DNA Test for Patients at Average Risk for Colorectal Cancer

10/07/2024

Stephanie Holland ;

Based on results from the BLUE-C study, the FDA has approved the Cologuard Plus™ test for patients 45 years and older at average risk for colorectal cancer.

Based on results from the BLUE-C...

10/07/2024

Oncology

Conference Coverage

Addition of Ribociclib Decreases Risk of Invasive and Distant Disease Recurrence Among Patients With HR-Positive, HER2-Negative Breast Cancer

10/04/2024

Stephanie Holland ;

Landmark 4-year analysis results...

10/04/2024

Oncology

News

Determining Optimal Daunorubicin Dosing and 7 + 3 Induction Cycles for Frontline AML Treatment

10/04/2024

Amber Denham ;

High-dose daunorubicin once daily using standard 7 + 3 induction did not significantly improve response rates among patients with newly diagnosed acute myeloid leukemia and did not lead to higher remission rates or improved survival when...

High-dose daunorubicin once...

10/04/2024

Oncology

News

Luspatercept Improves Anemia Among Patients With Myelofibrosis With or Without Transfusion Dependence

10/04/2024

Amber Denham ;

Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.

Luspatercept improved anemia and...

10/04/2024

Oncology

FDA Approval

FDA Approves Neoadjuvant/Adjuvant Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer

10/03/2024

Stephanie Holland ;

Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...

Based on results from the...

10/03/2024

Oncology

News

Investigating Low-Dose Subcutaneous Decitabine Treatment for Patients With Myelofibrosis

10/02/2024

Amber Denham ;

According to a prospective phase 2 trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained declines in circulating CD34+ cell counts were associated with response to hypomethylating agent decitabine treatment for...

According to a prospective phase...

10/02/2024

Oncology

News

Adjuvant Aspirin Shows Protective Effect Among Patients With PIK3CA-Mutant Colon Cancer

10/02/2024

Allison Casey ;

The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.

The phase 3 SAKK 41/13 trial...

10/02/2024

Oncology

News

Luspatercept as Novel Standard of Care for ESA-Naive Patients With Transfusion-Dependent, Lower-Risk MDS

10/02/2024

Amber Denham ;

Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.

Luspatercept provides a new...

10/02/2024

Oncology

Conference Coverage

Addition of Novel IgG1 Monoclonal Antibody to Chemoimmunotherapy Shows Promise in Extensive-Stage Small Cell Lung Cancer

10/01/2024

Stephanie Holland ;

According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...

According to interim analysis...

10/01/2024

Oncology

FDA Approval

FDA Approves Selpercatinib for Adult and Pediatric Patients With Advanced or Metastatic Medullary Thyroid Cancer

09/27/2024

Stephanie Holland ;

Based on results from the phase 3 LIBRETTO-531 study, the FDA has granted traditional approval to selpercatinib for adult and pediatric patients 2 years and older with advanced or metastatic medullary thyroid cancer harboring a RET mutation.

Based on results from the phase...

09/27/2024

Oncology